BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Currently however, except in some specific examples such as the BCR-ABL1 fusion in CML, and NPM1 or FLT3 mutations in de novo AML, molecular data are not associated with optimal clinical and therapeutic exploitation in the clinic.